Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 11/20 | 0.38 |
| ▸ | LCK | P06239 | 5/20 | 0.38 |
| ▸ | KDR | P35968 | 5/20 | 0.38 |
| ▸ | TEK | Q02763 | 5/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12031349 | 0.84 | ADK (0.41) | RETLCKKDRTEKSRC | |
| SCHEMBL24837761 | 0.83 | PRMT5 (0.37) | RETKDRSRCPRMT5WDR77 | |
| SCHEMBL20052484 | 0.79 | PI4KA (0.52) | — | |
| SCHEMBL20052485 | 0.78 | PRMT5 (0.38) | PRMT5WDR77 | |
| SCHEMBL12031062 | 0.78 | PRMT5 (0.38) | PRMT5WDR77 | |
| SCHEMBL8140442 | 0.78 | PRMT5 (0.38) | PRMT5WDR77 | |
| SCHEMBL19049972 | 0.74 | AHCY (0.33) | KDRSRCPRMT5WDR77 | |
| SCHEMBL19049958 | 0.73 | XDH (0.41) | — | |
| SCHEMBL24837548 | 0.73 | EGFR (0.35) | KDRTEKSRCPRMT5WDR77 | |
| SCHEMBL24837571 | 0.73 | EGFR (0.35) | KDRTEKSRCPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183373-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE | POLRMT, DUT, RNASE1 | RET 4535/4885LCK 2869/4885KDR 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.